ARCA biopharma Announces Additions to GENETIC-AF Leadership Team
Team Will Oversee Execution of GENETIC-AF Clinical Trial Evaluating Gencaro as
Potential Treatment for Atrial Fibrillation
BROOMFIELD, Colo. -- July 22, 2013
ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company developing
genetically-targeted therapies for cardiovascular diseases, today announced
that it has expanded the Company’s clinical trial leadership team with three
new hires in clinical development and quality assurance: vice president –
clinical development, senior director quality, and senior clinical program
These new hires will join existing ARCA employees in overseeing the execution
of GENETIC-AF, the Company’s Phase 2B/3 clinical trial evaluating Gencaro as a
potential treatment for atrial fibrillation.
“We are very pleased to have these industry professionals, who collectively
have over 45 years of clinical development and QA experience, join ARCA as key
members of our team,” said Dr. Michael R. Bristow, President and CEO. “Their
understanding of the drug development process and clinical trial execution
will be a tremendous asset as ARCA continues the development of Gencaro as a
potential treatment for atrial fibrillation.”
Christopher Dufton, PhD, Vice President, Clinical Development, was previously
Director of Clinical Research at Gilead Sciences. Prior to Gilead, Dr. Dufton
was Associate Director of Clinical Development at Myogen, Inc., where he was a
member of the development team responsible for the clinical program that led
to the approval of Letairis® (ambrisentan) for the treatment of pulmonary
arterial hypertension (PAH). Letairis is now approved in the U.S. and Europe
for the treatment of PAH.
Sharon Perry, Senior Director Quality, was previously Director of Quality
Assurance (QA) at Accera Pharma. Ms. Perry also brings additional relevant QA
experience from her prior work at Gilead Sciences, PR Pharmaceuticals and
Jennifer Merriweather, Senior Clinical Program Manager was previously Clinical
Program Manager at Gilead Sciences. Ms. Merriweather also brings additional
relevant clinical development experience from her work with Myogen, Inc.
About ARCA biopharma
ARCA biopharma is dedicated to developing genetically-targeted therapies for
cardiovascular diseases. The Company's lead product candidate, Gencaro^TM
(bucindolol hydrochloride), is an investigational, pharmacologically unique
beta-blocker and mild vasodilator being developed for atrial fibrillation.
ARCA has identified common genetic variations that it believes predict
individual patient response to Gencaro, giving it the potential to be the
first genetically-targeted atrial fibrillation prevention treatment. ARCA has
partnered with Medtronic, Inc. for the Phase 2B portion of the GENETIC-AF
trial. For more information please visit www.arcabiopharma.com.
Safe Harbor Statement
This press release contains "forward-looking statements" for purposes of the
safe harbor provided by the Private Securities Litigation Reform Act of 1995.
These statements include, but are not limited to, statements regarding
execution of the upcoming GENETIC-AF trial, the potential for genetic
variations to predict individual patient response to Gencaro, Gencaro’s
potential to treat atrial fibrillation, future treatment options for patients
with atrial fibrillation, and the potential for Gencaro to be the first
genetically-targeted atrial fibrillation prevention treatment. Such statements
are based on management's current expectations and involve risks and
uncertainties. Actual results and performance could differ materially from
those projected in the forward-looking statements as a result of many factors,
including, without limitation, the risks and uncertainties associated with:
the Company's financial resources and whether they will be sufficient to meet
the Company's business objectives and operational requirements; results of
earlier clinical trials may not be confirmed in future trials, the protection
and market exclusivity provided by the Company’s intellectual property; risks
related to the drug discovery and the regulatory approval process; and, the
impact of competitive products and technological changes. These and other
factors are identified and described in more detail in ARCA’s filings with the
SEC, including without limitation the Company’s annual report on Form 10-K for
the year ended December 31, 2012, and subsequent filings. The Company
disclaims any intent or obligation to update these forward-looking statements.
Investor Relations Advisory Solutions
Press spacebar to pause and continue. Press esc to stop.